Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Topotecan lacks third space sequestration.

H Gelderblom1, W J Loos, J Verweij

  • 1Department of Medical Oncology, Rotterdam Cancer Institute (Daniel den Hoed Kliniek) and University Hospital Rotterdam, The Netherlands.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|April 25, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prospective evaluation of genomics-guided off-label treatment.

Nature·2026
Same author

Prediction of Mutations and Outcome in Gastrointestinal Stromal Tumors with Deep Learning: A Multicenter, Multinational Study.

medRxiv : the preprint server for health sciences·2026
Same author

Health-related quality of life in patients with gastrointestinal stromal tumor: data from a real-world cohort compared with a normative population.

ESMO real world data and digital oncology·2026
Same author

A comprehensive assessment of the existing landscape of personalized cancer medicine in the European Union, on behalf of the PCM4EU consortium.

ESMO open·2025
Same author

PSMA expression and PSMA PET/CT imaging in metastatic soft tissue sarcoma patients, results of a prospective study.

European journal of nuclear medicine and molecular imaging·2025
Same author

Double burden: financial toxicity in patients with advanced soft tissue sarcoma at the start of first-line palliative chemotherapy: baseline data from the HOLISTIC study.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2025
Same journal

Presenting features and outcomes to standard systemic therapies in patients with MTAP-deleted advanced non-small cell lung cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Clinical Validation of a Multiplex Urine Biomarker Assay for Surveillance of Recurrent Bladder Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Claudin 18.2 Targeting: A Pan-Cancer Perspective.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

High-Sensitivity ctDNA Analysis Uncovers Relevant Signals Missed by NGS in Pancreatic Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Pediatric Brain Tumor Consortium phase 1 study of CD40 agonist sotigalimab in pediatric and young adult patients with recurrent CNS tumors and newly-diagnosed DIPG.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
See all related articles

This study found that topotecan pharmacokinetics are unaffected by pleural or ascitic fluid. Topotecan effectively penetrates these fluid spaces, suggesting potential benefits for local antitumor activity in cancer patients.

Area of Science:

  • Pharmacology
  • Oncology
  • Clinical Pharmacokinetics

Background:

  • Malignant solid tumors can lead to pleural effusions and ascites.
  • The impact of these fluid accumulations on drug pharmacokinetics is often unclear.
  • Topotecan is a camptothecin derivative used as an antitumor agent.

Purpose of the Study:

  • To investigate the influence of pleural and ascitic fluid on topotecan pharmacokinetics.
  • To assess topotecan's safety and efficacy in patients with third space fluid volumes.

Main Methods:

  • Four cancer patients received oral topotecan in the presence and absence of pleural/ascitic fluid.
  • Serial plasma and fluid samples were collected and analyzed using high-performance liquid chromatography.
  • Pharmacokinetic parameters including clearance, half-life, and drug penetration were evaluated.

Related Experiment Videos

Main Results:

  • Topotecan clearance remained consistent within individual patients, irrespective of fluid presence.
  • Terminal half-lives and lactone:total drug ratios in plasma were similar across dosing courses.
  • Significant topotecan penetration into pleural and ascitic fluid was observed, with a mean AUC ratio of 0.55.

Conclusions:

  • Topotecan administration is safe in patients with pleural effusions or ascites.
  • Substantial topotecan penetration into third space fluids suggests potential for enhanced local antitumor effects.